Total Q4 2025 revenue increased to 57620000, supported by 54300000 in net product revenue including 6200000 from Vafseo, while net loss improved to 12244000 compared to 22804000 in the prior year period.

Akebia achieved net income of $540,000 in Q3 2025, reversing a loss from the prior year, as total revenue rose to $58.8 million, supported by strong uptake of Vafseo and sustained Auryxia performance.

Akebia Therapeutics delivered a strong performance in Q2 2025, achieving a net income of $0.2 million, a substantial improvement from a net loss in the prior year. This turnaround was primarily fueled by a significant increase in total revenues to $62.5 million, largely due to the continued growth of Vafseo and increased Auryxia sales.

Akebia Therapeutics reported a net income of $6.1 million for Q1 2025, a significant improvement from a net loss of $18.0 million in Q1 2024, primarily due to total revenues increasing to $57.3 million, driven by the successful U.S. launch of Vafseo® and strong Auryxia® sales.

Akebia's Q4 2024 revenue declined 17.2% to $46.5 million due to lower Auryxia sales and reduced collaboration revenue. Net loss widened to $22.8 million compared to a small profit in Q4 2023. Operating expenses increased, driven by Vafseo's U.S. launch preparations. Cash reserves improved to $51.9 million, with further funding secured post-year-end.

Akebia Therapeutics reported total revenues of $37.4 million for the third quarter of 2024, compared to $42.0 million for the third quarter of 2023. The net loss for the quarter was $20.0 million, compared to a net loss of $14.5 million for the same period in the previous year. The company is preparing for the U.S. market availability of Vafseo expected in January 2025.

Akebia Therapeutics reported total revenues of $43.6 million and a net loss of $8.6 million for the second quarter of 2024. The company is focused on the commercial launch of Vafseo and contracting Auryxia through dialysis organizations.

Akebia Therapeutics reported total revenues of $32.6 million for Q1 2024, with net product revenues of $31.0 million from Auryxia. The company's net loss was $18.0 million. They are preparing for the launch of Vafseo in January 2025.

Akebia Therapeutics reported a net income of $0.6 million for Q4 2023, compared to a net loss of $6.1 million for Q4 2022. Total revenues for the quarter were $56.2 million, slightly up from $55.8 million in the same period last year. The company is preparing for the potential launch of vadadustat, pending FDA approval.

Akebia Therapeutics reported a decrease in total revenues to $42.0 million for the third quarter of 2023, compared to $48.7 million for the third quarter of 2022. Net loss was $14.5 million, significantly lower than the $54.1 million net loss in the same quarter of the previous year. The company's cash position remains strong, with $48.2 million in cash, cash equivalents, and restricted cash as of September 30, 2023.

Akebia Therapeutics reported a total revenue of $56.4 million for Q2 2023, with net product revenue of $42.2 million. The company experienced a net loss of $11.2 million, and expects to resubmit NDA for vadadustat in Q3 2023.

Akebia Therapeutics reported a total revenue of $40.1 million for Q1 2023, a decrease compared to $61.7 million for Q1 2022. Net loss was $26.2 million, a decrease from $62.4 million in the same quarter of the previous year. The company's cash and cash equivalents totaled $57.0 million as of March 31, 2023.

Akebia Therapeutics reported total revenue of $55.2 million for the fourth quarter of 2022, compared to $59.6 million for the fourth quarter of 2021. Net loss was $7.6 million for the fourth quarter of 2022, compared to $70.7 million for the fourth quarter of 2021. The company set Auryxia net product revenue guidance at $175-$180M for 2023.

Akebia Therapeutics reported a slight increase in total revenue to $49.0 million, driven by a 14.9% increase in Auryxia net product revenue, offset by a decrease in license and collaboration revenue. The company's net loss was reduced to $51.9 million. Akebia is focused on managing operating expenses and pursuing regulatory approval for vadadustat.

Akebia Therapeutics reported a net income of $29.3 million for Q2 2022, a significant turnaround from the $83.0 million net loss in Q2 2021. The company saw a 32.4% increase in net Auryxia product revenue, reaching $43.7 million. Additionally, Akebia regained full rights to vadadustat in the U.S., Europe, and other markets and increased its 2022 net Auryxia product revenue guidance to $170 - $175M.

Akebia Therapeutics reported a total revenue of $61.7 million for the first quarter of 2022, compared to $52.3 million for the first quarter of 2021. Net product revenue was $41.4 million, a 36% increase compared to Q1 2021. The company is focusing on Auryxia commercial success and exploring earlier-stage assets.

Akebia Therapeutics reported Q4 2021 financial results, with total revenue of $59.6 million, driven by net product revenue of $42.1 million and collaboration revenue of $17.5 million. The company's net loss was $70.7 million. Akebia is preparing for the potential launch of vadadustat, pending FDA approval.

Akebia Therapeutics reported a total revenue of $48.8 million for Q3 2021, a decrease compared to $60.0 million for Q3 2020, primarily due to lower collaboration revenue from Otsuka. Net loss was $59.5 million for the third quarter of 2021 compared to $60.0 million for the third quarter of 2020. Net product revenue for Auryxia was $36.8 million for the third quarter of 2021 compared to $34.4 million for the third quarter of 2020.

Akebia Therapeutics reported second quarter 2021 financial results, featuring increased Auryxia net product revenue and advancements in vadadustat's regulatory pathway, including FDA acceptance of the NDA filing with a PDUFA target action date of March 29, 2022.

Akebia Therapeutics reported a total revenue of $52.3 million for the first quarter of 2021, compared to $88.5 million for the first quarter of 2020. The net loss was $69.6 million, an increase from $60.7 million in the previous year. As of March 31, 2021, the company's cash, cash equivalents, and available-for-sale securities totaled $272.8 million.

Akebia Therapeutics reported a Q4 2020 total revenue of $56.7 million, a decrease compared to $69.6 million in Q4 2019. The net loss was $87.0 million, slightly better than the $94.5 million net loss in the same quarter of the previous year. The company's cash position remained strong with $268.7 million in cash, cash equivalents, and available-for-sale securities.

Akebia Therapeutics reported a total revenue of $60.0 million for the third quarter of 2020, compared to $92.0 million for the third quarter of 2019. The net loss for the quarter was $60.0 million, compared to $54.6 million for the same period in 2019. The company's cash, cash equivalents, and available-for-sale securities totaled $269.3 million as of September 30, 2020.

Akebia Therapeutics reported a total revenue of $90.1 million for the second quarter of 2020, compared to $100.8 million for the second quarter of 2019. Net loss was $175.8 million for the second quarter of 2020, compared to $58.2 million for the second quarter of 2019. Cash, cash equivalents and available-for-sale securities as of June 30, 2020 were $295.3 million.

Akebia Therapeutics, Inc. announced positive top-line results from INNO2VATE and reported financial results for the first quarter ended March 31, 2020. The company's cash runway extends well into 2021.

Akebia Therapeutics reported total revenue of $69.6 million for Q4 2019, compared to $59.9 million for Q4 2018. The company's net loss for the quarter was $94.5 million, compared to $60.1 million for the same period in the previous year. The company's cash, cash equivalents and available-for-sale securities as of December 31, 2019 were $147.7 million.